Sodium Fluoride
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB09325 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 13 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | epiglottitis | KG + DL |
| 2 | urinary tract infection (disease) | KG + DL |
| 3 | gonococcal urethritis | KG + DL |
| 4 | Ureaplasma urethritis | KG + DL |
| 5 | uterine inflammatory disease | KG + DL |
| 6 | xanthogranulomatous pyelonephritis | KG + DL |
| 7 | laryngitis | KG + DL |
| 8 | urogenital tuberculosis | KG + DL |
| 9 | biotin metabolic disease | KG + DL |
| 10 | abdominal tuberculosis | KG + DL |
| 11 | sequela of COVID-19 | KG + DL |
| 12 | hepatitis C induced liver cirrhosis | KG + DL |
| 13 | post-infectious neuralgia | KG + DL |
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.